960 related articles for article (PubMed ID: 7901757)
1. Substitutions of different regions of the third cytoplasmic loop of the thyrotropin (TSH) receptor have selective effects on constitutive, TSH-, and TSH receptor autoantibody-stimulated phosphoinositide and 3',5'-cyclic adenosine monophosphate signal generation.
Kosugi S; Okajima F; Ban T; Hidaka A; Shenker A; Kohn LD
Mol Endocrinol; 1993 Aug; 7(8):1009-20. PubMed ID: 7901757
[TBL] [Abstract][Full Text] [Related]
2. The middle portion in the second cytoplasmic loop of the thyrotropin receptor plays a crucial role in adenylate cyclase activation.
Kosugi S; Kohn LD; Akamizu T; Mori T
Mol Endocrinol; 1994 Apr; 8(4):498-509. PubMed ID: 7914349
[TBL] [Abstract][Full Text] [Related]
3. Mutation of alanine 623 in the third cytoplasmic loop of the rat thyrotropin (TSH) receptor results in a loss in the phosphoinositide but not cAMP signal induced by TSH and receptor autoantibodies.
Kosugi S; Okajima F; Ban T; Hidaka A; Shenker A; Kohn LD
J Biol Chem; 1992 Dec; 267(34):24153-6. PubMed ID: 1332945
[TBL] [Abstract][Full Text] [Related]
4. Identification of separate determinants on the thyrotropin receptor reactive with Graves' thyroid-stimulating antibodies and with thyroid-stimulating blocking antibodies in idiopathic myxedema: these determinants have no homologous sequence on gonadotropin receptors.
Kosugi S; Ban T; Akamizu T; Kohn LD
Mol Endocrinol; 1992 Feb; 6(2):168-80. PubMed ID: 1349156
[TBL] [Abstract][Full Text] [Related]
5. Identification of thyroid-stimulating antibody-specific interaction sites in the N-terminal region of the thyrotropin receptor.
Kosugi S; Ban T; Kohn LD
Mol Endocrinol; 1993 Jan; 7(1):114-30. PubMed ID: 8095322
[TBL] [Abstract][Full Text] [Related]
6. Receptor cross-talk can optimize assays for autoantibodies to the thyrotropin receptor: effect of phenylisopropyladenosine on adenosine 3',5'-monophosphate and inositol phosphate levels in rat FRTL-5 thyroid cells.
Hidaka A; Okajima F; Ban T; Kosugi S; Kondo Y; Kohn LD
J Clin Endocrinol Metab; 1993 Nov; 77(5):1164-9. PubMed ID: 8077307
[TBL] [Abstract][Full Text] [Related]
7. The intracellular region adjacent to plasma membrane (residues 684-692) of the thyrotropin receptor is important for phosphoinositide signaling but not for agonist-induced adenylate cyclase activation.
Kosugi S; Mori T
Biochem Biophys Res Commun; 1994 Mar; 199(3):1497-503. PubMed ID: 8147896
[TBL] [Abstract][Full Text] [Related]
8. The extracellular domain of the TSH receptor has an immunogenic epitope reactive with Graves' IgG but unrelated to receptor function as well as determinants having different roles for high affinity TSH binding and the activity of thyroid-stimulating autoantibodies.
Kosugi S; Akamizu T; Takai O; Prabhakar BS; Kohn LD
Thyroid; 1991; 1(4):321-30. PubMed ID: 1726785
[TBL] [Abstract][Full Text] [Related]
9. Graves' immunoglobulins activate phospholipase A2 by recognizing specific epitopes on thyrotropin receptor.
Di Cerbo A; Di Paola R; Menzaghi C; De Filippis V; Tahara K; Corda D; Kohn LD
J Clin Endocrinol Metab; 1999 Sep; 84(9):3283-92. PubMed ID: 10487700
[TBL] [Abstract][Full Text] [Related]
10. Use of thyrotropin receptor (TSHR) mutants to detect stimulating TSHR antibodies in hypothyroid patients with idiopathic myxedema, who have blocking TSHR antibodies.
Kosugi S; Ban T; Akamizu T; Valente W; Kohn LD
J Clin Endocrinol Metab; 1993 Jul; 77(1):19-24. PubMed ID: 8100829
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades.
Parma J; Van Sande J; Swillens S; Tonacchera M; Dumont J; Vassart G
Mol Endocrinol; 1995 Jun; 9(6):725-33. PubMed ID: 8592518
[TBL] [Abstract][Full Text] [Related]
12. Characterization of recombinant monoclonal antithyrotropin receptor antibodies (TSHRAbs) derived from lymphocytes of patients with Graves' disease: epitope and binding study of two stimulatory TSHRAbs.
Akamizu T; Moriyama K; Miura M; Saijo M; Matsuda F; Nakao K
Endocrinology; 1999 Apr; 140(4):1594-601. PubMed ID: 10098493
[TBL] [Abstract][Full Text] [Related]
13. Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2011 Feb; 21(2):169-76. PubMed ID: 20954819
[TBL] [Abstract][Full Text] [Related]
14. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
[TBL] [Abstract][Full Text] [Related]
15. Thyrotropin (TSH) receptor antibodies (TSHrAb) can inhibit TSH-mediated cyclic adenosine 3',5'- monophosphate production in thyroid cells by either blocking TSH binding or affecting a step subsequent to TSH binding.
Dallas JS; Cunningham SJ; Patibandla SA; Seetharamaiah GS; Morris JC; Tahara K; Kohn LD; Prabhakar BS
Endocrinology; 1996 Aug; 137(8):3329-39. PubMed ID: 8754759
[TBL] [Abstract][Full Text] [Related]
16. The formation of thyrotropin receptor (TSHR) antibodies in a Graves' animal model requires the N-terminal segment of the TSHR extracellular domain.
Kikuoka S; Shimojo N; Yamaguchi KI; Watanabe Y; Hoshioka A; Hirai A; Saito Y; Tahara K; Kohn LD; Maruyama N; Kohno Y; Niimi H
Endocrinology; 1998 Apr; 139(4):1891-8. PubMed ID: 9528975
[TBL] [Abstract][Full Text] [Related]
17. Thyrotropin, like luteinizing hormone (LH) and chorionic gonadotropin (CG), increases cAMP and inositol phosphate levels in cells with recombinant human LH/CG receptor.
Hidaka A; Minegishi T; Kohn LD
Biochem Biophys Res Commun; 1993 Oct; 196(1):187-95. PubMed ID: 8216292
[TBL] [Abstract][Full Text] [Related]
18. Thyrotropin stimulation of the lutropin/choriogonadotropin receptor: different sites mediate agonist activity and high affinity binding.
Hidaka A; Ban T; Panesar NS; Minegishi T; Kohn LD; Tahara K
Thyroid; 1994; 4(4):447-57. PubMed ID: 7711510
[TBL] [Abstract][Full Text] [Related]
19. Detection of functionally different types of pathological autoantibodies against thyrotropin receptor in Graves' patients sera by luminescent immunoprecipitation analysis.
Minich WB; Loos U
Exp Clin Endocrinol Diabetes; 2000; 108(2):110-9. PubMed ID: 10826518
[TBL] [Abstract][Full Text] [Related]
20. Characterization of monoclonal thyroid-stimulating and thyrotropin binding-inhibiting autoantibodies from a Hashimoto's patient whose children had intrauterine and neonatal thyroid disease.
Kohn LD; Suzuki K; Hoffman WH; Tombaccini D; Marcocci C; Shimojo N; Watanabe Y; Amino N; Cho BY; Kohno Y; Hirai A; Tahara K
J Clin Endocrinol Metab; 1997 Dec; 82(12):3998-4009. PubMed ID: 9398703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
